🔎 Trials Near Me

Home › COPD

Pag-aaral pangklinika para sa COPD na nagre-recruit sa U.S.

98 pag-aaral para sa COPD ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.

Mga lungsod na may pinakamaraming pag-aaral

Ayos sa estado

Mga pag-aaral na kamakailan lamang in-update

Opisyal na teksto ng pag-aaral (English)

Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF

Nagre-recruit
Edad 40 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT05934565

: Vascular Function in Health and Disease

Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT02966665

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Nagre-recruitPhase 2
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07759245

A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)

Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07793409

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

Nagre-recruit
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06035120

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

Nagre-recruitPhase 2
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07646587

Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD

Nagre-recruitPhase 4
Edad 60 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT07816835

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Nagre-recruitPhase 2
Edad 40 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07082738

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

Nagre-recruitPhase 2
Edad 40 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07059091

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06878261

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06883305

COPD Exacerbation Follow Up

Nagre-recruitObservasyonal na pag-aaral
Edad 40 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07118306

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06603246

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

Nagre-recruitObservasyonal na pag-aaral
Edad 40 pataas · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07612878

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

Nagre-recruitPhase 2/3
Edad 35 hanggang 80 · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT07363694

Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction

Nagre-recruit
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT05257681

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

Nagre-recruitPhase 2
Edad 40 pataas · Lahat ng kasarian · Na-update Ago 27, 2026 · NCT07037836

Rademikibart IV for Acute Asthma and COPD Exacerbation

Nagre-recruitPhase 2
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Ago 27, 2026 · NCT07705737

Photon-counting CT in Chest Imaging

Nagre-recruit
Lahat ng edad · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT07031336

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.